Clinical sources for the animation

S1: Wah et al. CAIN feasibility trial protocol, 2025
https://link.springer.com/article/10.1007/s00270-025-04035-5
Scope: Abstract; Histotripsy Device; Index-Procedure Ultrasound Imaging Inclusion/Exclusion; Histotripsy Treatment. Primary renal protocol, not outcome evidence.

S2: Wah et al. Early Clinical Histotripsy Treatment of Renal Cell Carcinoma, 2025
https://link.springer.com/article/10.1007/s00270-025-04023-9
Scope: Treatment-position and planning paragraphs; later imaging paragraph; procedural considerations. One renal case, not a rate or general prognosis.

S3: NYU Langone: Histotripsy Makes Its Clinical Debut in NYC
https://physicianfocus.nyulangone.org/histotripsy-makes-its-clinical-debut-in-nyc/
Scope: Opening mechanism paragraph. Describes cavitation, acellular debris and reabsorption. Clinical service described is liver; do not transfer its outcomes or recovery claims to kidney.

S4: Hall et al. Histotripsy of rabbit renal tissue in vivo: temporal histologic trends, 2007
https://pubmed.ncbi.nlm.nih.gov/17949317/
Scope: Abstract results/conclusions. Animal renal tissue; later resorption, fibrosis and a contour defect were reported. No human timing or unchanged-contour guarantee.

S5: NYU renal histotripsy research listing
https://clinicaltrials.med.nyu.edu/clinicaltrial/2321/histosonics-edison-system-treatment/
Scope: Brief description; trial identifier NCT05820087. Supports renal research context only.

S6: NCI renal histotripsy trial listing
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-00069
Scope: Description; status closed to accrual. Guard against an unsupported recruitment invitation. Trial and device names stay in sources, outside the film.

Evidence limits
The renal protocol describes research methods; the renal clinical report describes one case. Animal observations do not establish human outcomes or a healing timetable. The NYU liver article is used for the mechanism only. The film includes no outcome rates, treatment comparisons, renal FDA-authorization claim, recovery promise or recruitment invitation. The hollow view is explicitly an illustration with the fluid hidden; it does not show actual draining or immediate physical emptying.